China Sky One
Medical, Inc. ("China Sky One Medical" or "he Company") (Nasdaq: CSKI), a
leading fully integrated pharmaceutical company developing and producing
over-the-counter drugs in the People's Republic of China ("PRC"), today
announced that Heilongjiang Tianlong Pharmaceutical Company ("Tianlong"), the
Company's wholly owned subsidiary, will change its R&D focus from external use
medicines to antibiotics and cardiac drugs.
The change in Tianlong's R&D strategy is designed to build a solid
foundation for the Company's future growth. Tianlong possesses one of the most
complete portfolios of external use medicines in China. By focusing on the
development of antibiotics and cardiac drugs, China Sky One Medical expects
that Tianlong will be able to benefit from the increasing demand for
prescription drugs as basic medical insurance coverage expands in China.
Antibiotics represent the largest drug category in China, accounting for
20%-25% of total sales of western medicines. Medicines for the treatment of
cardiac diseases represent the third largest drug category following cancer
drugs, and account for roughly 15% of total sales of chemical medicines in
The Company plans to introduce five new antibiotics including Cefmetazole
Sodium for injection, Cefodizime Sodium for injection, Aztreonam for injection,
Teicoplanin for injection, Voriconazole Powder Solution for infusion, and two
cardiac drugs, Amrinone for injection and Milrinone for injection. The Company
has completed a feasibility analysis and experimental research, and has
mastered the production technology. As a result of this initiative, China Sky
One Medical will strengthen its distribution channel for prescription drugs by
engaging more qualified commercial medical companies.
"We look forward to more breakthroughs in the development of antibiotics
and cardiac drugs and will strive to obtain final SFDA approvals for the
production of our seven new drugs as soon as possible," said Mr. Yan-Qing Liu,
Chairman and CEO of China Sky One Medical. "The demand for better health care
and drugs is increasing rapidly, and we see this as an opportunity to
capitalize on the growth of China's fragmented pharmaceutical industry."
SOURCE China Sky One Medical, Inc.